RUNX1 and acute myeloid leukemia: Runx1 acts as a transcriptional repressor of VEGF-A by directly binding to its promoter and has been suggested to have anti-angiogenic activity in AML cells [68] and in a mouse HCC model [69] (Table 2), indicating that RUNX1 performs an anti-angiogenic function by suppressing VEGF-A expression.